Molecular Diagnostic Testing for Infectious Diseases Global Market Size, Strategies and Forecasts 2016 to 2020

Description:
Genetic knowledge of virus takes centre stage in diagnosis.

Our facts and support = Your success.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing. Infectious disease testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:
- changing demographics
- emerging economies and global prosperity
- biotechnology advances in genetics
- pathogen evolution
- climate change
- globalization
- automation

Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

This research makes you the expert in your organization.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Contents:
1. Introduction and Market Definition
   1.1 What is Molecular Diagnostics
   1.2 The Diagnostics Revolution
   1.3 Market Definition
      1.3.1 Volumes
      1.3.2 Prices
      1.3.3 Revenue Market Size
   1.4 Methodology
   1.4.1 Authors
   1.4.2 Sources
   1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
      1.5.1 U.S. Medicare Expenditures for Clinical Testing
2. The Infectious Diseases - Market Analysis by Disease
2.1 HIV - Human Immunodeficiency Virus (AIDS)
  2.1.1 Virology
  2.1.1.1 Classification
  2.1.1.2 Structure and genome
  2.1.1.3 Tropism
  2.1.1.4 Replication cycle
  2.1.1.5 Genetic variability
  2.1.2 Diagnosis
  2.1.3 Testing
  2.1.3.1 Antibody tests
  2.1.3.2 Point of Care Tests (POCT)
  2.1.3.4 Antigen Tests
  2.1.3.5 Nucleic acid-based tests (NAT)
  2.1.3.6 Other tests used in HIV treatment
  2.1.4 Market Opportunity Analysis
2.2 HBV - Hepatitis B
  2.2.1 Virology
  2.2.1.1 Genome
  2.2.1.2 Pathogenesis
  2.2.1.3 Hepatitis B virus replication
  2.2.1.4 Serotypes and genotypes
  2.2.2 Mechanisms
  2.2.3 Diagnosis
  2.2.4 Market Opportunity Analysis
2.3 HCV - Hepatitis C
  2.3.1 Taxonomy
  2.3.2 Structure
  2.3.2.2 Genome
  2.3.3 Molecular biology
  2.3.4 Replication
  2.3.5 Genotypes
  2.3.5.1 Clinical importance
  2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
  2.4.1 Virology
  2.4.1.1 E6/E7 proteins
  2.4.1.2 Role in cancer
  2.4.1.3 E2 research
  2.4.1.4 Latency period
  2.4.1.5 Clearance
  2.4.2 Diagnosis
  2.4.2.1 Cervical testing
  2.4.2.2 Oral testing
  2.4.2.3 Testing men
  2.4.2.4 Other testing
  2.4.3 Market Opportunity Analysis
2.5 Influenza
  2.5.1 Virology
  2.5.1.1 Types of virus
  2.5.1.2 Influenzavirus A
  2.5.1.3 Influenzavirus B
  2.5.1.4 Influenzavirus C
  2.5.1.5 Structure, properties, and subtype nomenclature
  2.5.1.6 Replication
  2.5.2 Testing
  2.5.2.1 Advantages/Disadvantages of Molecular Assays
  2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
  2.6.1 Gonorrhea
  2.6.1.1 Diagnosis
  2.6.1.2 Screening
  2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Testing
2.6.3.1 Nucleic acid amplification tests (NAATs).
2.6.3.2 Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3 Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 Blood Screening
2.10.1 Collection and Testing
2.10.2 FDA Approved Multiplex Assays
2.10.3 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 Supplier/pharmaceutical
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale
3.3.3 Physician Office Lab's
3.3.4 Physician's and POCT
3.4 Profiles of Key MDx Companies
3.4.1 Roche Molecular Diagnostics
3.4.2 Illumina
3.4.3 Hologic
3.4.4 Agilent/Dako
3.4.5 Qiagen
3.4.6 Myriad Genetics
3.4.7 Becton, Dickinson & Co.
3.4.8 Abbott Laboratories
3.4.9 Cepheid
3.4.10 Genomic Health
3.4.11 Grifols
3.4.12 bioMérieux
3.4.13 Foundation Medicine
3.4.14 Agenda
3.4.15 Thermo Fisher
3.4.16 Signal Genetics LLC
3.4.17 Siemens Healthcare
4. Market Trends
4.1 Factors Driving Growth
  4.1.1 New Diagnostic Definitions Create New Markets
  4.1.2 Aging Population a Boon for Diagnostics.
  4.1.3 Pharmacogenomics Drives Further Growth.
  4.1.4 Point of Care Testing can increase demand
  4.1.5 Liquid Biopsy
4.2 Factors Limiting Growth
  4.2.1 Increased Competition Lowers Price
  4.2.2 Lower Costs.
  4.2.3 Testing usage analysis curtailing growth.
  4.2.4 Wellness has a downside
  4.2.5 Point of Care Testing
4.3 Instrumentation and Automation
  4.3.1 Instruments Key to Market Share
  4.3.2 Bioinformatics Plays a Role.
4.4 Diagnostic Technology Development
  4.4.1 Next Generation Sequencing Fuels a Revolution
  4.4.2 Impact of NGS on pricing
  4.4.3 POCT/Self Testing Disruptive Force
  4.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
  4.4.5 CGES Testing, A Brave New World
  4.4.6 Biochips/Giant magneto resistance based assay
5. Molecular Dx - Infectious Disease Recent Developments
  5.1 Recent Developments - Importance and How to Use This Section
  5.1.1 Importance of These Developments
  5.1.2 How to Use This Section
  5.3 Qvella raises $20 million U.S. Series A round
  5.4 Enzo Biochem Demonstrates Greater Sensitivity of Its AmpiProbe™ Platform for Molecular Diagnostics
  5.5 Cepheid's PCR Panel Test First To Receive CLIA Waiver
  5.6 Great Basin Announces Modifications to Series C Warrants
  5.7 Quest Diagnostics Streamlines Hepatitis C Virus Lab Testing
  5.8 Janssen Diagnostics Garners CE-IVD Mark for Flu/RSV Panel
  5.9 Microbix Announces First Molecular Diagnostics Agreement
  5.10 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
  5.11 Seegene Gets CE Mark for GI Infectious Disease Test
  5.12 Luminex Q3 Revenues Jump 7 Percent; Firm Beats Estimates
  5.13 MRIGlobal to develop system for diagnosis of infectious diseases
  5.14 Roche Acquires Microbial Dx Firm GeneWeave for up to $425M
  5.15 Mediven's MDx Tests Get CE-IVD Mark
  5.16 Focus Diagnostics Flu, RSV Test Kit Cleared with Additional Strains
  5.17 Seegene, QIAGEN to Collaborate to Develop Multiplex Molecular Diagnostic Assays
  5.18 Roche POC MDx Flu Test Gets CLIA Waiver
  5.19 Roche Gets FDA Approval for Cobas MDx Systems; HBV, HCV Viral Load Tests
  5.20 Luminex Begins Clinical Testing of Aries Diagnostic System, HSV Assay

  6.1 United States of America
  6.1.1 HIV - Volumes, Prices, Revenues
  6.1.2 HBV - Volumes, Prices, Revenues
  6.1.3 HCV - Volumes, Prices, Revenues
  6.1.4 HPV - Volumes, Prices, Revenues
  6.1.5 FLU - Volumes, Prices, Revenues
  6.1.6 CHGC - Volumes, Prices, Revenues
  6.1.7 Tb - Volumes, Prices, Revenues
  6.1.8 MRSA - Volumes, Prices, Revenues
  6.1.9 VRE - Volumes, Prices, Revenues
  6.1.10 Screening/Other - Volumes, Prices, Revenues
  6.2 Canada
  6.2.1 HIV - Volumes, Prices, Revenues
RESEARCH AND MARKETS

6.2.2 HBV - Volumes, Prices, Revenues
6.2.3 HCV - Volumes, Prices, Revenues
6.2.4 HPV - Volumes, Prices, Revenues
6.2.5 FLU - Volumes, Prices, Revenues
6.2.6 CHGC - Volumes, Prices, Revenues
6.2.7 Tb - Volumes, Prices, Revenues
6.2.8 MRSA - Volumes, Prices, Revenues
6.2.9 VRE - Volumes, Prices, Revenues
6.2.10 Screening/Other - Volumes, Prices, Revenues

7. Country Markets - Europe
7.1 France
7.1.1 HIV - Volumes, Prices, Revenues
7.1.2 HBV - Volumes, Prices, Revenues
7.1.3 HCV - Volumes, Prices, Revenues
7.1.4 HPV - Volumes, Prices, Revenues
7.1.5 FLU - Volumes, Prices, Revenues
7.1.6 CHGC - Volumes, Prices, Revenues
7.1.7 Tb - Volumes, Prices, Revenues
7.1.8 MRSA - Volumes, Prices, Revenues
7.1.9 VRE - Volumes, Prices, Revenues
7.1.10 Screening/Other - Volumes, Prices, Revenues
7.2 Germany
7.2.1 HIV - Volumes, Prices, Revenues
7.2.2 HBV - Volumes, Prices, Revenues
7.2.3 HCV - Volumes, Prices, Revenues
7.2.4 HPV - Volumes, Prices, Revenues
7.2.5 FLU - Volumes, Prices, Revenues
7.2.6 CHGC - Volumes, Prices, Revenues
7.2.7 Tb - Volumes, Prices, Revenues
7.2.8 MRSA - Volumes, Prices, Revenues
7.2.9 VRE - Volumes, Prices, Revenues
7.2.10 Screening/Other - Volumes, Prices, Revenues
7.3 United Kingdom
7.3.1 HIV - Volumes, Prices, Revenues
7.3.2 HBV - Volumes, Prices, Revenues
7.3.3 HCV - Volumes, Prices, Revenues
7.3.4 HPV - Volumes, Prices, Revenues
7.3.5 FLU - Volumes, Prices, Revenues
7.3.6 CHGC - Volumes, Prices, Revenues
7.3.7 Tb - Volumes, Prices, Revenues
7.3.8 MRSA - Volumes, Prices, Revenues
7.3.9 VRE - Volumes, Prices, Revenues
7.3.10 Screening/Other - Volumes, Prices, Revenues
7.4 Spain
7.4.1 HIV - Volumes, Prices, Revenues
7.4.2 HBV - Volumes, Prices, Revenues
7.4.3 HCV - Volumes, Prices, Revenues
7.4.4 HPV - Volumes, Prices, Revenues
7.4.5 FLU - Volumes, Prices, Revenues
7.4.6 CHGC - Volumes, Prices, Revenues
7.4.7 Tb - Volumes, Prices, Revenues
7.4.8 MRSA - Volumes, Prices, Revenues
7.4.9 VRE - Volumes, Prices, Revenues
7.4.10 Screening/Other - Volumes, Prices, Revenues
7.5 Italy
7.5.1 HIV - Volumes, Prices, Revenues
7.5.2 HBV - Volumes, Prices, Revenues
7.5.3 HCV - Volumes, Prices, Revenues
7.5.4 HPV - Volumes, Prices, Revenues
7.5.5 FLU - Volumes, Prices, Revenues
7.5.6 CHGC - Volumes, Prices, Revenues
7.5.7 Tb - Volumes, Prices, Revenues
7.5.8 MRSA - Volumes, Prices, Revenues
7.5.9 VRE - Volumes, Prices, Revenues
7.5.10 Screening/Other - Volumes, Prices, Revenues
7.6 Switzerland
7.6.1 HIV - Volumes, Prices, Revenues
7.6.2 HBV - Volumes, Prices, Revenues
7.6.3 HCV - Volumes, Prices, Revenues
7.6.4 HPV - Volumes, Prices, Revenues
7.6.5 FLU - Volumes, Prices, Revenues
7.6.6 CHGC - Volumes, Prices, Revenues
7.6.7 Tb - Volumes, Prices, Revenues
7.6.8 MRSA - Volumes, Prices, Revenues
7.6.9 VRE - Volumes, Prices, Revenues
7.6.10 Screening/Other - Volumes, Prices, Revenues
7.7 Czech Republic
7.7.1 HIV - Volumes, Prices, Revenues
7.7.2 HBV - Volumes, Prices, Revenues
7.7.3 HCV - Volumes, Prices, Revenues
7.7.4 HPV - Volumes, Prices, Revenues
7.7.5 FLU - Volumes, Prices, Revenues
7.7.6 CHGC - Volumes, Prices, Revenues
7.7.7 Tb - Volumes, Prices, Revenues
7.7.8 MRSA - Volumes, Prices, Revenues
7.7.9 VRE - Volumes, Prices, Revenues
7.7.10 Screening/Other - Volumes, Prices, Revenues
7.8 Belgium
7.8.1 HIV - Volumes, Prices, Revenues
7.8.2 HBV - Volumes, Prices, Revenues
7.8.3 HCV - Volumes, Prices, Revenues
7.8.4 HPV - Volumes, Prices, Revenues
7.8.5 FLU - Volumes, Prices, Revenues
7.8.6 CHGC - Volumes, Prices, Revenues
7.8.7 Tb - Volumes, Prices, Revenues
7.8.8 MRSA - Volumes, Prices, Revenues
7.8.9 VRE - Volumes, Prices, Revenues
7.8.10 Screening/Other - Volumes, Prices, Revenues
7.9 Russia
7.9.1 HIV - Volumes, Prices, Revenues
7.9.2 HBV - Volumes, Prices, Revenues
7.9.3 HCV - Volumes, Prices, Revenues
7.9.4 HPV - Volumes, Prices, Revenues
7.9.5 FLU - Volumes, Prices, Revenues
7.9.6 CHGC - Volumes, Prices, Revenues
7.9.7 Tb - Volumes, Prices, Revenues
7.9.8 MRSA - Volumes, Prices, Revenues
7.9.9 VRE - Volumes, Prices, Revenues
7.9.10 Screening/Other - Volumes, Prices, Revenues
7.10 Remainder of Europe and Former Soviet Union
7.10.1 HIV - Volumes, Prices, Revenues
7.10.2 HBV - Volumes, Prices, Revenues
7.10.3 HCV - Volumes, Prices, Revenues
7.10.4 HPV - Volumes, Prices, Revenues
7.10.5 FLU - Volumes, Prices, Revenues
7.10.6 CHGC - Volumes, Prices, Revenues
7.10.7 Tb - Volumes, Prices, Revenues
7.10.8 MRSA - Volumes, Prices, Revenues
7.10.9 VRE - Volumes, Prices, Revenues
7.10.10 Screening/Other - Volumes, Prices, Revenues

8. Country Markets - Asia Pacific
8.1 China
8.1.1 HIV - Volumes, Prices, Revenues
8.1.2 HBV - Volumes, Prices, Revenues
<table>
<thead>
<tr>
<th>Region</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8.1.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.1.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td>Japan</td>
<td>8.2.1 HIV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.2 HBV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.2.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td>South Korea</td>
<td>8.3.1 HIV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.2 HBV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.3.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td>India</td>
<td>8.4.1 HIV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.2 HBV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.4.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td>Australia</td>
<td>8.5.1 HIV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.2 HBV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.5.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td>Rest of Asia Pacific</td>
<td>8.6.1 HIV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.2 HBV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.3 HCV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.4 HPV - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.5 FLU - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.6 CHGC - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.7 Tb - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.8 MRSA - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.9 VRE - Volumes, Prices, Revenues</td>
</tr>
<tr>
<td></td>
<td>8.6.10 Screening/Other - Volumes, Prices, Revenues</td>
</tr>
</tbody>
</table>
9. Country Markets - Latin America, Africa & The Middle East
9.1 Brazil
9.1.1 HIV - Volumes, Prices, Revenues
9.1.2 HBV - Volumes, Prices, Revenues
9.1.3 HCV - Volumes, Prices, Revenues
9.1.4 HPV - Volumes, Prices, Revenues
9.1.5 FLU - Volumes, Prices, Revenues
9.1.6 CHGC - Volumes, Prices, Revenues
9.1.7 Tb - Volumes, Prices, Revenues
9.1.8 MRSA - Volumes, Prices, Revenues
9.1.9 VRE - Volumes, Prices, Revenues
9.1.10 Screening/Other - Volumes, Prices, Revenues
9.2 Mexico
9.2.1 HIV - Volumes, Prices, Revenues
9.2.2 HBV - Volumes, Prices, Revenues
9.2.3 HCV - Volumes, Prices, Revenues
9.2.4 HPV - Volumes, Prices, Revenues
9.2.5 FLU - Volumes, Prices, Revenues
9.2.6 CHGC - Volumes, Prices, Revenues
9.2.7 Tb - Volumes, Prices, Revenues
9.2.8 MRSA - Volumes, Prices, Revenues
9.2.9 VRE - Volumes, Prices, Revenues
9.2.10 Screening/Other - Volumes, Prices, Revenues
9.3 Remainder of Latin America
9.3.1 HIV - Volumes, Prices, Revenues
9.3.2 HBV - Volumes, Prices, Revenues
9.3.3 HCV - Volumes, Prices, Revenues
9.3.4 HPV - Volumes, Prices, Revenues
9.3.5 FLU - Volumes, Prices, Revenues
9.3.6 CHGC - Volumes, Prices, Revenues
9.3.7 Tb - Volumes, Prices, Revenues
9.3.8 MRSA - Volumes, Prices, Revenues
9.3.9 VRE - Volumes, Prices, Revenues
9.3.10 Screening/Other - Volumes, Prices, Revenues
9.4 Africa & The Middle East
9.4.1 HIV - Volumes, Prices, Revenues
9.4.2 HBV - Volumes, Prices, Revenues
9.4.3 HCV - Volumes, Prices, Revenues
9.4.4 HPV - Volumes, Prices, Revenues
9.4.5 FLU - Volumes, Prices, Revenues
9.4.6 CHGC - Volumes, Prices, Revenues
9.4.7 Tb - Volumes, Prices, Revenues
9.4.8 MRSA - Volumes, Prices, Revenues
9.4.9 VRE - Volumes, Prices, Revenues
9.4.10 Screening/Other - Volumes, Prices, Revenues
10. Global Market Summary
10.1 Global Market
10.1.1 HIV - Volumes, Prices, Revenues
10.1.2 HBV - Volumes, Prices, Revenues
10.1.3 HCV - Volumes, Prices, Revenues
10.1.4 HPV - Volumes, Prices, Revenues
10.1.5 FLU - Volumes, Prices, Revenues
10.1.6 CHGC - Volumes, Prices, Revenues
10.1.7 Tb - Volumes, Prices, Revenues
10.1.8 MRSA - Volumes, Prices, Revenues
10.1.9 VRE - Volumes, Prices, Revenues
10.1.10 Screening/Other - Volumes, Prices, Revenues
Appendices
I. United States Medicare System: January 2016 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests

List of Tables:
Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
Table 2 Classification of HIV Species
Table 3 HIV Tests - CMS Codes & Prices
Table 4 Current HIV Molecular Tests and Instruments Used
Table 5 HBV Tests - CMS Codes & Prices
Table 6 HCV Tests - CMS Codes & Prices
Table 7 HPV Clearance Rates
Table 8 HPV Tests - CMS Codes & Prices
Table 9 HPV Tests, Technology, Types
Table 10 Types of Influenza Tests
Table 11 Influenza Tests - CMS Codes & Prices
Table 12 FDA Cleared Molecular Assays for Influenza
Table 13 FDA Cleared NAAT CTGC Tests
Table 14 CTGC NAAT Target Sequences and Possible False Reactions
Table 15 Influenza Tests - CMS Codes & Prices
Table 16 FDA Approved MDx Tests for Tuberculosis
Table 17 Tuberculosis Tests - CMS Codes & Prices
Table 18 FDA Approved Tests for MRSA
Table 19 MRSA Tests - CMS Codes & Prices
Table 20 FDA Approved Tests for VRE
Table 21 VRE Tests - CMS Codes & Prices
Table 22 FDA Approved Multiplex Assays
Table 23 Market Players by Type
Table 24 Clinical Laboratory Departments and Segments
Table 25 Laboratory Management Focus - Different Approaches
Table 26 Key Segmentation Variables Going Forward
Table 27 Five Factors Driving Growth
Table 28 Four Factors Limiting Growth
Table 29 Key Diagnostic Laboratory Technology Trends
Table 30 Next Generation Sequencing Technologies - Speed and Cost
Table 31 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 32 MDx HBV - Volume Price and Revenue Forecast
Table 33 HCV - Volume Price and Revenue Forecast
Table 34 HPV - Volume Price and Revenue Forecast
Table 35 FLU - Volume Price and Revenue Forecast
Table 36 CHGC - Volume Price and Revenue Forecast
Table 37 Tb - Volume Price and Revenue Forecast
Table 38 MRSA - Volume Price and Revenue Forecast
Table 39 VRE - Volume Price and Revenue Forecast
Table 40 Screening/Other - Volume Price and Revenue Forecast
Table 41 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 42 MDx HBV - Volume Price and Revenue Forecast
Table 43 HCV - Volume Price and Revenue Forecast
Table 44 HPV - Volume Price and Revenue Forecast
Table 45 FLU - Volume Price and Revenue Forecast
Table 46 CHGC - Volume Price and Revenue Forecast
Table 47 Tb - Volume Price and Revenue Forecast
Table 48 MRSA - Volume Price and Revenue Forecast
Table 49 VRE - Volume Price and Revenue Forecast
Table 50 Screening/Other - Volume Price and Revenue Forecast
Table 51 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 52 MDx HBV - Volume Price and Revenue Forecast
Table 53 HCV - Volume Price and Revenue Forecast
Table 54 HPV - Volume Price and Revenue Forecast
Table 55 FLU - Volume Price and Revenue Forecast
Table 56 CHGC - Volume Price and Revenue Forecast
Table 57 Tb - Volume Price and Revenue Forecast
Table 58 MRSA - Volume Price and Revenue Forecast
Table 59 VRE - Volume Price and Revenue Forecast
Table 60 Screening/Other - Volume Price and Revenue Forecast
Table 61 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 62 MDx HBV - Volume Price and Revenue Forecast
Table 63 HCV - Volume Price and Revenue Forecast
Table 64 HPV - Volume Price and Revenue Forecast
Table 65 FLU - Volume Price and Revenue Forecast
Table 66 CHGC - Volume Price and Revenue Forecast
Table 67 Tb - Volume Price and Revenue Forecast
Table 68 MRSA - Volume Price and Revenue Forecast
Table 69 VRE - Volume Price and Revenue Forecast
Table 70 Screening/Other - Volume Price and Revenue Forecast
Table 71 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 72 MDx HBV - Volume Price and Revenue Forecast
Table 73 HCV - Volume Price and Revenue Forecast
Table 74 HPV - Volume Price and Revenue Forecast
Table 75 FLU - Volume Price and Revenue Forecast
Table 76 CHGC - Volume Price and Revenue Forecast
Table 77 Tb - Volume Price and Revenue Forecast
Table 78 MRSA - Volume Price and Revenue Forecast
Table 79 VRE - Volume Price and Revenue Forecast
Table 80 Screening/Other - Volume Price and Revenue Forecast
Table 81 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 82 MDx HBV - Volume Price and Revenue Forecast
Table 83 HCV - Volume Price and Revenue Forecast
Table 84 HPV - Volume Price and Revenue Forecast
Table 85 FLU - Volume Price and Revenue Forecast
Table 86 CHGC - Volume Price and Revenue Forecast
Table 87 Tb - Volume Price and Revenue Forecast
Table 88 MRSA - Volume Price and Revenue Forecast
Table 89 VRE - Volume Price and Revenue Forecast
Table 90 Screening/Other - Volume Price and Revenue Forecast
Table 91 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 92 MDx HBV - Volume Price and Revenue Forecast
Table 93 HCV - Volume Price and Revenue Forecast
Table 94 HPV - Volume Price and Revenue Forecast
Table 95 FLU - Volume Price and Revenue Forecast
Table 96 CHGC - Volume Price and Revenue Forecast
Table 97 Tb - Volume Price and Revenue Forecast
Table 98 MRSA - Volume Price and Revenue Forecast
Table 99 VRE - Volume Price and Revenue Forecast
Table 100 Screening/Other - Volume Price and Revenue Forecast
Table 101 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 102 MDx HBV - Volume Price and Revenue Forecast
Table 103 HCV - Volume Price and Revenue Forecast
Table 104 HPV - Volume Price and Revenue Forecast
Table 105 FLU - Volume Price and Revenue Forecast
Table 106 CHGC - Volume Price and Revenue Forecast
Table 107 Tb - Volume Price and Revenue Forecast
Table 108 MRSA - Volume Price and Revenue Forecast
Table 109 VRE - Volume Price and Revenue Forecast
Table 110 Screening/Other - Volume Price and Revenue Forecast
Table 111 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 112 MDx HBV - Volume Price and Revenue Forecast
Table 113 HCV - Volume Price and Revenue Forecast
Table 114 HPV - Volume Price and Revenue Forecast
Table 115 FLU - Volume Price and Revenue Forecast
Table 116 CHGC - Volume Price and Revenue Forecast
Table 117 Tb - Volume Price and Revenue Forecast
Table 118 MRSA - Volume Price and Revenue Forecast
Table 119 VRE - Volume Price and Revenue Forecast
Table 120 Screening/Other - Volume Price and Revenue Forecast
Table 121 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 185 FLU - Volume Price and Revenue Forecast
Table 186 CHGC - Volume Price and Revenue Forecast
Table 187 Tb - Volume Price and Revenue Forecast
Table 188 MRSA - Volume Price and Revenue Forecast
Table 189 VRE - Volume Price and Revenue Forecast
Table 190 Screening/Other - Volume Price and Revenue Forecast
Table 191 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 192 MDx HBV - Volume Price and Revenue Forecast
Table 193 HCV - Volume Price and Revenue Forecast
Table 194 HPV - Volume Price and Revenue Forecast
Table 195 FLU - Volume Price and Revenue Forecast
Table 196 CHGC - Volume Price and Revenue Forecast
Table 197 Tb - Volume Price and Revenue Forecast
Table 198 MRSA - Volume Price and Revenue Forecast
Table 199 VRE - Volume Price and Revenue Forecast
Table 200 Screening/Other - Volume Price and Revenue Forecast
Table 201 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 202 MDx HBV - Volume Price and Revenue Forecast
Table 203 HCV - Volume Price and Revenue Forecast
Table 204 HPV - Volume Price and Revenue Forecast
Table 205 FLU - Volume Price and Revenue Forecast
Table 206 CHGC - Volume Price and Revenue Forecast
Table 207 Tb - Volume Price and Revenue Forecast
Table 208 MRSA - Volume Price and Revenue Forecast
Table 209 VRE - Volume Price and Revenue Forecast
Table 210 Screening/Other - Volume Price and Revenue Forecast
Table 211 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 212 MDx HBV - Volume Price and Revenue Forecast
Table 213 HCV - Volume Price and Revenue Forecast
Table 214 HPV - Volume Price and Revenue Forecast
Table 215 FLU - Volume Price and Revenue Forecast
Table 216 CHGC - Volume Price and Revenue Forecast
Table 217 Tb - Volume Price and Revenue Forecast
Table 218 MRSA - Volume Price and Revenue Forecast
Table 219 VRE - Volume Price and Revenue Forecast
Table 220 Screening/Other - Volume Price and Revenue Forecast
Table 221 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 222 MDx HBV - Volume Price and Revenue Forecast
Table 223 HCV - Volume Price and Revenue Forecast
Table 224 HPV - Volume Price and Revenue Forecast
Table 225 FLU - Volume Price and Revenue Forecast
Table 226 CHGC - Volume Price and Revenue Forecast
Table 227 Tb - Volume Price and Revenue Forecast
Table 228 MRSA - Volume Price and Revenue Forecast
Table 229 VRE - Volume Price and Revenue Forecast
Table 230 Screening/Other - Volume Price and Revenue Forecast
Table 231 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 232 MDx HBV - Volume Price and Revenue Forecast
Table 233 HCV - Volume Price and Revenue Forecast
Table 234 HPV - Volume Price and Revenue Forecast
Table 235 FLU - Volume Price and Revenue Forecast
Table 236 CHGC - Volume Price and Revenue Forecast
Table 237 Tb - Volume Price and Revenue Forecast
Table 238 MRSA - Volume Price and Revenue Forecast
Table 239 VRE - Volume Price and Revenue Forecast
Table 240 Screening/Other - Volume Price and Revenue Forecast
Table 241 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 242 MDx HBV - Volume Price and Revenue Forecast
Table 243 HCV - Volume Price and Revenue Forecast
Table 244 HPV - Volume Price and Revenue Forecast
Table 245 FLU - Volume Price and Revenue Forecast
Table 246 CHGC - Volume Price and Revenue Forecast
Table 247 Tb - Volume Price and Revenue Forecast
Table 248 MRSA - Volume Price and Revenue Forecast
Table 249 VRE - Volume Price and Revenue Forecast
Table 250 Screening/Other - Volume Price and Revenue Forecast
Table 251 HIV Infectious Disease - Volume Price and Revenue Forecast
Table 252 MDx HBV - Volume Price and Revenue Forecast
Table 253 HCV - Volume Price and Revenue Forecast
Table 254 HPV - Volume Price and Revenue Forecast
Table 255 FLU - Volume Price and Revenue Forecast
Table 256 CHGC - Volume Price and Revenue Forecast
Table 257 Tb - Volume Price and Revenue Forecast
Table 258 MRSA - Volume Price and Revenue Forecast
Table 259 VRE - Volume Price and Revenue Forecast
Table 260 Screening/Other - Volume Price and Revenue Forecast
Table 261 2015 Clinical Lab Fee Schedule

List of Figures:
Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
Figure 2 HIV Virion
Figure 3 Diagram of the HIV Replication Cycle
Figure 4 The Structure of the HBV Virus
Figure 5 Hepatitis B Replication
Figure 6 Structure of the HCV Virus
Figure 7 HCV Replication Cycle
Figure 8 Structure of the Influenza Virion
Figure 9 Influenza Replication
Figure 10 Scanning Electronmicrograph of Tuberculosis
Figure 11 Chart of Market Shares of Key MDx Companies
Figure 12 Percentage of World Population Over 65

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3505457/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Molecular Diagnostic Testing for Infectious Diseases Global Market Size, Strategies and Forecasts 2016 to 2020 |
| Web Address: | http://www.researchandmarkets.com/reports/3505457/ |
| Office Code: | SCDKVUNG |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4495</td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td>USD 7495</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 10495</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ___________________________  First Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB9853308313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp